Having placed leaders into roles like this repeatedly, we wrote this to give a practitioner’s view rather than generic advice. Hiring a CEO for a medical device company is not the same as hiring a general CEO, because the FDA regulatory pathway shapes strategy, timelines, capital needs, and risk in ways a leader from outside the sector may never have managed. A medical device CEO must genuinely understand the regulatory pathways their products depend on, since a CEO who misjudges FDA strategy can sink the company regardless of general executive skill.
Key Takeaways
- A medical device CEO must genuinely understand FDA regulatory pathways.
- Pathway choice (510(k), De Novo, PMA) shapes strategy, timelines, and capital.
- Regulatory missteps can be existential, so pathway fluency is not optional.
- Assess for real regulatory judgment, not just general executive pedigree.
- Match the CEO to your product’s specific regulatory profile.
Why FDA Fluency Defines the Role
In medical devices, the FDA regulatory pathway is not a back-office concern; it drives the entire business. Whether a product goes through 510(k) clearance, the De Novo route, or full premarket approval (PMA) determines development timelines, clinical evidence requirements, capital needs, and go-to-market strategy. A CEO who does not genuinely understand these pathways can make strategic decisions that prove unworkable or catastrophically slow once regulatory reality asserts itself. This is why a medical device CEO must bring real regulatory fluency, not a general executive who treats FDA strategy as someone else’s problem, since the pathway shapes what the company can achieve and when.
The Pathways and What They Demand
The major pathways differ sharply. A 510(k) clearance rests on demonstrating substantial equivalence to a predicate device, generally a faster, lower-evidence route. The De Novo pathway addresses novel low-to-moderate-risk devices without a predicate. Premarket approval (PMA) applies to higher-risk devices and demands rigorous clinical evidence, a longer, costlier road. A CEO must understand which pathway their products face, what it demands in evidence and time, and how it shapes strategy and capital. In assessment, probe how a candidate has actually navigated these pathways, decisions made, timelines managed, regulatory strategy set, rather than whether they can merely name them.
Regulatory Strategy as Business Strategy
In medical devices, regulatory strategy and business strategy are inseparable: when a product can launch, what evidence it needs, how much capital the regulatory road consumes, and what claims the company can make all flow from the regulatory pathway. A strong medical device CEO integrates regulatory strategy into business strategy, planning capital, timelines, and commercial moves around regulatory reality, and works closely with regulatory and clinical leadership. A CEO who treats regulatory as a downstream compliance function, rather than a strategic driver, misjudges the business. Weight the candidate’s ability to think about regulatory and business strategy together, since in this sector they are one.
What This Looks Like in Practice
A board hiring a medical device CEO assesses genuine regulatory fluency alongside general leadership: it probes how the candidate has navigated the specific pathways relevant to the company’s products, how they integrated regulatory strategy into business decisions, and how they worked with regulatory and clinical teams. It matches the CEO to the product’s regulatory profile, a PMA-heavy company needs different regulatory depth than a 510(k) business. It does not hire an impressive generalist who treats FDA strategy as a delegated concern.
The Mistake Employers Keep Making
The most common mistake is hiring a distinguished general executive, or a leader from an unregulated industry, and assuming their business skill will carry the regulatory dimension. It often does not: a CEO who misjudges pathway strategy, underestimates evidence requirements, or sets timelines and capital plans divorced from regulatory reality can derail the company. The board mistakes general excellence for the regulatory fluency the sector demands, and discovers the gap only when regulatory reality collides with the CEO’s plan.
The Major FDA Pathways at a Glance
| Pathway | Applies To | What It Demands |
|---|---|---|
| 510(k) | Devices with a predicate | Substantial equivalence, faster route |
| De Novo | Novel low-to-moderate-risk devices | Classification without a predicate |
| PMA | Higher-risk devices | Rigorous clinical evidence, longer road |
| Strategic implication | All | Shapes timelines, capital, and claims |
The Bottom Line
A medical device CEO must genuinely understand the FDA pathways their products depend on, since pathway choice shapes strategy, timelines, capital, and risk, and a CEO who misjudges it can sink the company, so hire for real regulatory fluency and judgment matched to your product’s regulatory profile, not general executive pedigree alone. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.
Related Reading
For more, see Top Qualities to Look for in a VP of Regulatory Affairs (MedTech), Why MedTech Companies Need Specialized Executive Recruiters, What Boards Should Know Before a MedTech CEO Search.
Frequently Asked Questions
- Q: Why must a medical device CEO understand FDA pathways?
- A: Because the regulatory pathway drives development timelines, evidence requirements, capital needs, and go-to-market strategy, so a CEO who misjudges it can derail the company.
- Q: What are the main FDA pathways?
- A: 510(k) clearance (substantial equivalence to a predicate), the De Novo route (novel low-to-moderate-risk devices), and premarket approval (PMA) for higher-risk devices requiring rigorous clinical evidence.
- Q: Can a CEO from another industry run a device company?
- A: Only with genuine regulatory fluency; a leader who treats FDA strategy as a delegated compliance concern may misjudge the strategy, timelines, and capital the pathway demands.
- Q: How do I assess regulatory judgment in a CEO?
- A: Probe how the candidate has actually navigated the relevant pathways, set regulatory strategy, managed timelines and evidence, and integrated regulatory into business decisions, not just whether they can define the pathways.
- Q: Does the right CEO depend on our product?
- A: Yes; match the CEO to your product’s regulatory profile, since a PMA-heavy, high-risk-device company needs different regulatory depth than a 510(k)-driven business.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
